BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 9384478)

  • 1. Progressive disease after ABMT for Hodgkin's disease.
    Bolwell BJ; Kalaycio M; Goormastic M; Dannley R; Andresen SW; Lichtin A; Overmoyer B; Pohlman B
    Bone Marrow Transplant; 1997 Nov; 20(9):761-5. PubMed ID: 9384478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Salvage chemotherapy with mini-BEAM for relapsed or refractory Hodgkin's disease prior to autologous peripheral blood stem cell transplantation.
    Fernández-Jiménez MC; Canales MA; Ojeda E; de Bustos JG; Aguado MJ; Hernández-Navarro F
    Haematologica; 1999 Nov; 84(11):1007-11. PubMed ID: 10553161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 'Relative' chemotherapy sensitivity: the impact of number of salvage regimens prior to autologous stem cell transplant for relapsed and refractory aggressive non-Hodgkin's lymphoma.
    Chen CI; Roitman D; Tsang R; Stewart AK; Keating A; Crump M
    Bone Marrow Transplant; 2002 Dec; 30(12):885-91. PubMed ID: 12476281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes.
    Wheeler C; Eickhoff C; Elias A; Ibrahim J; Ayash L; McCauley M; Mauch P; Schwartz G; Eder JP; Mazanet R; Ferrara J; Rimm IJ; Guinan E; Bierer B; Gilliland G; Churchill WH; Ault K; Parsons S; Antman K; Schnipper L; Tepler I; Gaynes L; Frei E; Kadin M; Antin J
    Biol Blood Marrow Transplant; 1997 Jun; 3(2):98-106. PubMed ID: 9267670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR).
    Lazarus HM; Loberiza FR; Zhang MJ; Armitage JO; Ballen KK; Bashey A; Bolwell BJ; Burns LJ; Freytes CO; Gale RP; Gibson J; Herzig RH; LeMaistre CF; Marks D; Mason J; Miller AM; Milone GA; Pavlovsky S; Reece DE; Rizzo JD; van Besien K; Vose JM; Horowitz MM
    Bone Marrow Transplant; 2001 Feb; 27(4):387-96. PubMed ID: 11313668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose intensification with autologous stem cell transplantation in relapsed and resistant Hodgkin's disease.
    Anselmo AP; Cavalieri E; Meloni G; Alimena G; Cantonetti M; Maurizi Enrici R; Tosti ME; Falchetto Osti M; Gianfelici V; Mandelli F
    Haematologica; 2002 May; 87(5):507-11. PubMed ID: 12010664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer].
    Avigdor A; Hardan I; Shpilberg O; Raanani P; Grotto I; Ben-Bassat I
    Harefuah; 2000 Sep; 139(5-6):174-9, 248, 247. PubMed ID: 11062945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of preparatory regimen and source of hematopoietic cells on outcome of autotransplantation for non-Hodgkin's lymphoma.
    Stockerl-Goldstein KE; Horning SJ; Negrin RS; Chao NJ; Hu WW; Long GD; Hoppe RT; Amylon MD; Brown BW; Wong RM; Blume KG
    Biol Blood Marrow Transplant; 1996 May; 2(2):76-85. PubMed ID: 9118302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double dose-intensive chemotherapy with autologous stem cell support for relapsed and refractory testicular cancer: the University of Michigan experience and literature review.
    Ayash LJ; Clarke M; Silver SM; Braun T; Uberti J; Ratanatharathorn V; Reynolds C; Ferrara J; Broun ER; Adams PT
    Bone Marrow Transplant; 2001 May; 27(9):939-47. PubMed ID: 11436104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma.
    Benekli M; Smiley SL; Younis T; Czuczman MS; Hernandez-Ilizaliturri F; Bambach B; Battiwalla M; Padmanabhan S; McCarthy PL; Hahn T
    Bone Marrow Transplant; 2008 Apr; 41(7):613-9. PubMed ID: 18071290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autotransplantation for relapsed or refractory Hodgkin's disease: long-term follow-up and analysis of prognostic factors.
    Lancet JE; Rapoport AP; Brasacchio R; Eberly S; Raubertas RF; Linder T; Muhs A; Duerst RE; Abboud CN; Packman CH; DiPersio JF; Constine LS; Rowe JM; Liesveld JL
    Bone Marrow Transplant; 1998 Aug; 22(3):265-71. PubMed ID: 9720740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autologous stem cell transplantation (ASCT) for poor prognostic Hodgkin's disease (HD): comparative results with two CBV regimens and importance of disease status at transplant.
    Arranz R; Tomás JF; Gil-Fernández JJ; Martínez-Chamorro C; Granados E; Alegre A; Figuera A; Vázquez L; Cámara R; Fernández-Rañada JM
    Bone Marrow Transplant; 1998 Apr; 21(8):779-86. PubMed ID: 9603401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose therapy with autologous or allogeneic transplantation as salvage therapy for small cleaved cell lymphoma of follicular center cell origin.
    Stein RS; Greer JP; Goodman S; Kallianpur A; Ahmed MS; Wolff SN
    Bone Marrow Transplant; 1999 Feb; 23(3):227-33. PubMed ID: 10084253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation.
    Stewart DA; Guo D; Glück S; Morris D; Chaudhry A; deMetz C; Klassen J; Brown CB; Russell JA
    Bone Marrow Transplant; 2000 Aug; 26(4):383-8. PubMed ID: 10982284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [High dose chemoradiotherapy with autologous hemotopoietic stem cell transplantation for treatment of patients with advanced Hodgkin's lymphoma: a report of 11 cases].
    Zhou SY; Shi YK; He XH; Han XH; Liu P; Yang JL; Zhou AP; Feng FY
    Ai Zheng; 2002 Apr; 21(4):405-8. PubMed ID: 12452021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous stem cell transplantation for poor prognosis Hodgkin's disease in first complete remission: a retrospective study from the Spanish GEL-TAMO cooperative group.
    Sureda A; Mataix R; Hernández-Navarro F; Jarque I; Lahuerta JJ; Tomás JF; Brunet S; Caballero D; Conde E; León A; Fernández MN; López A; Maldonado J; Bengoechea E; Callís M; Carrera D; García-Conde J; García-Laraña J; Moraleda JM; Morey M; Rifón J; Sierra J; Torres A; Domingo-Albós A
    Bone Marrow Transplant; 1997 Aug; 20(4):283-8. PubMed ID: 9285542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Durability of remission after ABMT for NHL: the importance of the 2-year evaluation point.
    Bolwell B; Goormastic M; Andresen S
    Bone Marrow Transplant; 1997 Mar; 19(5):443-8. PubMed ID: 9052909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autologous stem cell transplantation for advanced Hodgkin's disease in children. Spanish group for BMT in children (GETMON), Spain.
    Verdeguer A; Pardo N; Madero L; Martinez A; Bureo E; Fernández JM; Muñoz A; Olivé T; Fernández-Delgado R; Cubells J; Diaz MA; Sastre A
    Bone Marrow Transplant; 2000 Jan; 25(1):31-4. PubMed ID: 10654011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second autologous stem cell transplant for multiply relapsed Hodgkin's disease.
    Lin TS; Avalos BR; Penza SL; Marcucci G; Elder PJ; Copelan EA
    Bone Marrow Transplant; 2002 May; 29(9):763-7. PubMed ID: 12040474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.